Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 30 Jul 2018
At a glance
- Drugs Alemtuzumab (Primary) ; Anakinra (Primary) ; Etanercept (Primary) ; Liraglutide (Primary) ; Plerixafor (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 20 Jul 2018 Planned primary completion date changed from 30 Jun 2022 to 30 Aug 2022.
- 21 Nov 2017 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.